Catalyst Pharmaceutical Partners Inc. (CPRX) Rating Increased to Overweight at Piper Jaffray Cos.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) was upgraded by research analysts at Piper Jaffray Cos. from a “neutral” rating to an “overweight” rating in a research note issued on Wednesday. The brokerage presently has a $4.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price objective points to a potential upside of 194.12% from the company’s current price.
Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Catalyst Pharmaceutical Partners from a “buy” rating to a “hold” rating in a report on Thursday, June 9th. HC Wainwright reiterated a “buy” rating on shares of Catalyst Pharmaceutical Partners in a report on Tuesday, June 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $3.56.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded down 2.16% on Wednesday, hitting $1.36. The company had a trading volume of 669,110 shares. The company has a 50 day moving average of $1.09 and a 200-day moving average of $0.89. Catalyst Pharmaceutical Partners has a 12-month low of $0.51 and a 12-month high of $3.55. The company’s market cap is $112.70 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/catalyst-pharmaceutical-partners-inc-cprx-rating-increased-to-overweight-at-piper-jaffray-cos.html
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. On average, analysts forecast that Catalyst Pharmaceutical Partners will post ($0.25) earnings per share for the current year.
Several large investors have recently modified their holdings of the company. Royal Bank of Canada bought a new stake in shares of Catalyst Pharmaceutical Partners during the second quarter worth approximately $117,000. Oxford Asset Management raised its stake in shares of Catalyst Pharmaceutical Partners by 3.5% in the second quarter. Oxford Asset Management now owns 180,721 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 6,140 shares during the last quarter. DRW Securities LLC bought a new stake in shares of Catalyst Pharmaceutical Partners during the second quarter worth approximately $168,000. Paloma Partners Management Co bought a new stake in shares of Catalyst Pharmaceutical Partners during the second quarter worth approximately $200,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Catalyst Pharmaceutical Partners during the first quarter worth approximately $206,000. Institutional investors and hedge funds own 30.64% of the company’s stock.
Catalyst Pharmaceutical Partners Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.